Prosecution Insights
Prosecution Insights
14 pending office actions • 12 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (36%) |
| §112 only | 2 (14%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 2 (14%) |
| Multi-statute (no §101) | 4 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| WELLS, LAUREN QUINLAN | 1 | 46.6% | +61.8% |
| NATARAJAN, MEERA | 1 | 62.3% | +17.6% |
| BORI, IBRAHIM D | 1 | 44.2% | +38.7% |
| DUNN, LINDSAY MICHELLE | 1 | 100.0% | +0.0% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| JADHAO, SAMADHAN JAISING | 1 | 50.0% | +47.1% |
| LEE, CHIHYI NMN | 1 | 32.9% | +58.5% |
| CHICKS, ASHLI ARIANA | 1 | 63.2% | +45.9% |
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712407 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | HABTE, KAHSAY | — |
| 18490500 | ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS | DUNN, LINDSAY MICHELLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 24d overdue |
| 18697655 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND REVERSE TRANSCRIPTASE INHIBITOR | WELLS, LAUREN QUINLAN | — |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | — |
| 18007012 | NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253846 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CHICKS, ASHLI ARIANA | 147d overdue |
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 24d overdue |
| 18697655 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND REVERSE TRANSCRIPTASE INHIBITOR | WELLS, LAUREN QUINLAN | — |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | — |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | BORI, IBRAHIM D | — |
| 18283781 | DRUG COMBINATION OF TOLL-LIKE RECEPTOR 7 AGONIST AND ANTI-PD-L1 ANTIBODY | JADHAO, SAMADHAN JAISING | — |
| 18019612 | COMBINED MEDICATION FOR TREATING SOFT TISSUE SARCOMA | KAUFMAN, CLAIRE M | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1629 | 1 |
| 1644 | 1 |
| 1642 | 1 |
| 1672 | 1 |
| 1628 | 1 |
| 1626 | 1 |
| 1674 | 1 |
| 1643 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18712407 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | HABTE, KAHSAY | — | §112 | Non-Final OA | — | Pending | May 22, 2024 |
| 18697655 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND REVERSE TRANSCRIPTASE INHIBITOR | WELLS, LAUREN QUINLAN | 1622 | §103§112 | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | — | §102§103§112 | Non-Final OA | — | Pending | Mar 11, 2024 |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | BORI, IBRAHIM D | 1629 | §103 | Final Rejection | — | Pending | Mar 07, 2024 |
| 18490500 | ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS | DUNN, LINDSAY MICHELLE | 1644 | §112DP | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18285511 | MULTI-SPECIFIC ANTIBODY TARGETING BCMA | PRIEST, JESSICA MARIE | 1642 | DP | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18283781 | DRUG COMBINATION OF TOLL-LIKE RECEPTOR 7 AGONIST AND ANTI-PD-L1 ANTIBODY | JADHAO, SAMADHAN JAISING | 1672 | §103§112DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 1628 | §102§103§112 | Final Rejection | 24d overdue | Pending | Jul 27, 2023 |
| 18253846 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CHICKS, ASHLI ARIANA | 1626 | §103 | Non-Final OA | 147d overdue | Pending | May 22, 2023 |
| 18019612 | COMBINED MEDICATION FOR TREATING SOFT TISSUE SARCOMA | KAUFMAN, CLAIRE M | 1674 | §103Other | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18007012 | NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION | BRISTOL, LYNN ANNE | 1643 | §103§112 | Non-Final OA | — | Pending | Jan 26, 2023 |
| 18001244 | CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE | ZAHORIK, AMANDA MARY | 1636 | §103 | Final Rejection | — | Pending | Dec 08, 2022 |
| 17792282 | PHARMACEUTICAL COMPOSITION OF TRICYCLIC PDE3/PDE4 DUAL INHIBITOR COMPOUND | HUANG, GIGI GEORGIANA | 1613 | §112 | Non-Final OA | 14d | Pending | Jul 12, 2022 |
| 17595519 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | CHEN, PO-CHIH | 1621 | §103 | Final Rejection | — | Pending | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial